Investors in Tilray Brands are facing a complex picture following the cannabis company’s latest earnings report. The figures for the second fiscal quarter of 2026 present a stark contrast: impressive top-line growth is being undercut by a deeper-than-anticipated loss per share, testing shareholder patience.
Profitability Challenges Eclipse Sales Growth
The headline numbers from the quarter tell two different stories. On one hand, Tilray achieved a new revenue record, generating $217.5 million. This represents a 3% year-over-year increase and surpassed market expectations. The growth was powered by two key divisions: the distribution business surged 26% to $85.3 million, while international cannabis revenue jumped by an even more robust 36%.
However, the bottom-line results dampen the enthusiasm from this sales performance. The company reported a loss per share (EPS) of -$0.41, which was significantly wider than the -$0.14 loss analysts had forecast. Although Tilray managed to reduce its absolute net loss to $44.9 million, the substantial miss on per-share earnings highlights persistent profitability hurdles.
Market Sentiment Remains Cautious
This divergence between revenue strength and earnings pressure is reflected in the analytical community’s stance. The predominant rating among experts is currently “Hold.” While they acknowledge the potential within Tilray’s expanding business segments, concerns are mounting over pressured margins.
Should investors sell immediately? Or is it worth buying Tilray?
Some researchers express a more bearish view. Zacks Investment Research has assigned the stock a “Strong Sell” rating (Rank 5), explicitly citing the missed profit expectations. In this context, a forward price-to-sales (P/S) ratio of 1.18x offers little consolation for investors seeking near-term recovery signals.
Strategic Focus and Sector Volatility
Management is continuing to prioritize its cost-reduction initiative, known as “Project 420,” in a bid to improve margins. The company has reaffirmed its full-year EBITDA guidance alongside these efforts. With a strong liquidity position of $291.6 million in cash and marketable securities, Tilray possesses a solid financial cushion to execute its strategic plans.
The path forward for the share price is now heavily dependent on the successful implementation of these efficiency measures. Furthermore, the broader cannabis sector remains inherently volatile. Pending regulatory decisions, especially concerning the potential reclassification of cannabis at the federal level in the United States, continue to loom as a major external uncertainty over the industry.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from January 15 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 15.
Tilray: Buy or sell? Read more here...
